- Home
- NUVB vs OEC Comparison
NUVB vs OEC Comparison
Compare NUVB & OEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- OEC
- Stock Information
- Founded
- NUVB 2018
- OEC 1862
- Country
- NUVB United States
- OEC Luxembourg
- Employees
- NUVB N/A
- OEC N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- OEC Major Chemicals
- Sector
- NUVB Health Care
- OEC Industrials
- Exchange
- NUVB Nasdaq
- OEC Nasdaq
- Market Cap
- NUVB 679.9M
- OEC 674.8M
- IPO Year
- NUVB N/A
- OEC 2014
- Fundamental
- Price
- NUVB $2.12
- OEC $10.88
- Analyst Decision
- NUVB Strong Buy
- OEC Buy
- Analyst Count
- NUVB 5
- OEC 2
- Target Price
- NUVB $8.20
- OEC $13.50
- AVG Volume (30 Days)
- NUVB 4.2M
- OEC 816.2K
- Earning Date
- NUVB 05-07-2025
- OEC 05-07-2025
- Dividend Yield
- NUVB N/A
- OEC 0.76%
- EPS Growth
- NUVB N/A
- OEC N/A
- EPS
- NUVB N/A
- OEC 0.46
- Revenue
- NUVB $10,957,000.00
- OEC $1,852,300,000.00
- Revenue This Year
- NUVB $95.27
- OEC N/A
- Revenue Next Year
- NUVB $345.44
- OEC $4.76
- P/E Ratio
- NUVB N/A
- OEC $23.67
- Revenue Growth
- NUVB N/A
- OEC N/A
- 52 Week Low
- NUVB $1.54
- OEC $9.59
- 52 Week High
- NUVB $3.97
- OEC $25.24
- Technical
- Relative Strength Index (RSI)
- NUVB 47.71
- OEC 44.07
- Support Level
- NUVB $2.14
- OEC $10.52
- Resistance Level
- NUVB $2.42
- OEC $11.10
- Average True Range (ATR)
- NUVB 0.16
- OEC 0.38
- MACD
- NUVB -0.01
- OEC 0.03
- Stochastic Oscillator
- NUVB 27.71
- OEC 30.38
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About OEC Orion S.A.
Orion SA is a manufacturer of carbon black products. Carbon black is a powdered form of carbon used to create the desired physical, electrical and optical qualities of various materials. The company's operating segments are Specialty Carbon Black and Rubber Carbon Black. It generates maximum revenue from the Rubber Carbon Black segment. Rubber Carbon Black segment is used in the reinforcement of rubber in tires and mechanical rubber goods. The Specialty Carbon Black segment is used as pigments and performance additives in coatings, polymers, printing and special applications. Geographically, it derives a majority of its revenue from Germany.